

Jorge Castillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2150708/publications.pdf>

Version: 2024-02-01

369
papers

12,984
citations

19657

61
h-index

33894

99
g-index

370
all docs

370
docs citations

370
times ranked

10585
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 372, 1430-1440.	27.0	810
2	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	1.4	382
3	The biology and treatment of plasmablastic lymphoma. <i>Blood</i> , 2015, 125, 2323-2330.	1.4	355
4	Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-120.	1.6	338
5	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	1.4	281
6	HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. <i>American Journal of Hematology</i> , 2008, 83, 804-809.	4.1	266
7	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. <i>Blood</i> , 2020, 135, 1912-1915.	1.4	253
8	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 241-250.	10.7	212
9	Diagnosis and Management of Hyponatremia in Cancer Patients. <i>Oncologist</i> , 2012, 17, 756-765.	3.7	188
10	Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2047-2053.	1.3	187
11	Survival of patients with marginal zone lymphoma. <i>Cancer</i> , 2013, 119, 629-638.	4.1	181
12	The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenström's Macroglobulinemia. <i>Leukemia</i> , 2015, 29, 169-176.	7.2	180
13	Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. <i>Blood</i> , 2012, 119, 4845-4850.	1.4	177
14	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood</i> , 2014, 124, 503-510.	1.4	168
15	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	1.4	161
16	Human immunodeficiency virus-associated plasmablastic lymphoma. <i>Cancer</i> , 2012, 118, 5270-5277.	4.1	147
17	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2755-2761.	1.6	142
18	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717.	4.9	138

#	ARTICLE	IF	CITATIONS
19	Diabetes and Risk of Non-Hodgkin's Lymphoma. <i>Diabetes Care</i> , 2008, 31, 2391-2397.	8.6	131
20	Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic Lymphoma. <i>Oncologist</i> , 2010, 15, 293-299.	3.7	128
21	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014, 25, 2211-2217.	1.2	126
22	Plasmablastic Lymphoma: A Systematic Review. <i>Scientific World Journal, The</i> , 2011, 11, 687-696.	2.1	124
23	Clonal architecture of <i>CXCR4</i> <i>WHIM</i> -like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 172, 735-744.	2.5	122
24	Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database. <i>American Journal of Hematology</i> , 2014, 89, 310-314.	4.1	120
25	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. <i>Blood</i> , 2017, 129, 2519-2525.	1.4	115
26	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	3.5	112
27	Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>British Journal of Haematology</i> , 2015, 169, 81-89.	2.5	110
28	Obesity but not overweight increases the incidence and mortality of leukemia in adults: A meta-analysis of prospective cohort studies. <i>Leukemia Research</i> , 2012, 36, 868-875.	0.8	107
29	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 1198-1208.	1.6	103
30	Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2014, 28, 1698-1704.	7.2	100
31	Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far. <i>Oncologist</i> , 2011, 16, 87-96.	3.7	99
32	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	1.6	98
33	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	4.6	96
34	<i>CXCR4</i> <i>WHIM</i> -like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant <i>MYD88</i> ^{L265P} -directed survival signalling in Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 168, 701-707.	2.5	95
35	HIV-Negative Plasmablastic Lymphoma: Not in the Mouth. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 185-189.	0.4	93
36	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. <i>Blood</i> , 2016, 127, 3237-3252.	1.4	93

#	ARTICLE	IF	CITATIONS
37	Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>Blood</i> , 2014, 123, 3999-4000.	1.4	91
38	Treatment Selection and Outcomes in Early-Stage Classical Hodgkin Lymphoma: Analysis of the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2015, 33, 625-633.	1.6	91
39	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. <i>Blood</i> , 2016, 128, 827-838.	1.4	91
40	Management of hematological malignancies during pregnancy. <i>American Journal of Hematology</i> , 2009, 84, 830-841.	4.1	90
41	The relation between cigarette smoking and risk of acute myeloid leukemia: An updated meta-analysis of epidemiological studies. <i>American Journal of Hematology</i> , 2014, 89, E125-32.	4.1	89
42	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016, 172, 709-715.	2.5	87
43	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	4.1	83
44	MYD88 wild-type Waldenström Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. <i>British Journal of Haematology</i> , 2018, 180, 374-380.	2.5	83
45	NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 8-19.	4.9	80
46	Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. <i>Leukemia Research</i> , 2013, 37, 1107-1115.	0.8	77
47	Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 994-1001.	1.6	76
48	Newer monoclonal antibodies for hematological malignancies. <i>Experimental Hematology</i> , 2008, 36, 755-768.	0.4	75
49	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 953-962.	4.1	75
50	EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 529-537.	4.1	74
51	CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 356-363.	2.5	73
52	ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. <i>Journal of Hematology and Oncology</i> , 2009, 2, 11.	17.0	72
53	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. <i>Blood Advances</i> , 2018, 2, 2937-2946.	5.2	72
54	Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: A Review. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1877-1884.	2.0	71

#	ARTICLE	IF	CITATIONS
55	Bortezomib in combination with infusional dose-adjusted <sc>EPOCH</sc> for the treatment of plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 352-355.	2.5	71
56	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	1.4	69
57	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. <i>British Journal of Haematology</i> , 2016, 175, 623-630.	2.5	68
58	EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. <i>American Journal of Hematology</i> , 2011, 86, 663-667.	4.1	65
59	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.6	65
60	Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 491-500.	4.1	64
61	CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 15-22.	4.1	64
62	Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. <i>Blood</i> , 2010, 116, 2897-2907.	1.4	63
63	The <sc>BCL</sc>2 antagonist <sc>ABT</sc>-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <i><sc>CXCR</sc>4</i> ^{<i>Wild</i>-type} and <i><sc>CXCR</sc>4</i> ^{<i>WHIM</i>} mutated Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 170, 134-138.	2.5	63
64	The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. <i>BMC Cancer</i> , 2016, 16, 564.	2.6	63
65	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	2.5	61
66	BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. <i>Blood</i> , 2018, 131, 2047-2059.	1.4	61
67	Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. <i>American Journal of Hematology</i> , 2018, 93, 511-517.	4.1	61
68	Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. <i>Leukemia and Lymphoma</i> , 2012, 53, 2378-2382.	1.3	58
69	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the <sc>IWWM</sc>-8 consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	2.5	58
70	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 177, 717-725.	2.5	58
71	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2018, 24, 3247-3252.	7.0	57
72	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	5.2	57

#	ARTICLE	IF	CITATIONS
73	EBV-Positive Diffuse Large B-Cell Lymphoma in Young Immunocompetent Individuals. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 512-516.	0.4	56
74	Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. <i>British Journal of Haematology</i> , 2017, 179, 339-341.	2.5	56
75	Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , 2013, 119, 3672-3679.	4.1	55
76	Bortezomib plus <sc>EPOCH</sc> is effective as frontline treatment in patients with plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 679-682.	2.5	55
77	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1032-1035.	4.1	53
78	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	1.6	53
79	Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, E312-3.	4.1	52
80	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. <i>Leukemia</i> , 2022, 36, 532-539.	7.2	50
81	Are We Training Our Fellows Adequately in Delivering Bad News to Patients? A Survey of Hematology/Oncology Program Directors. <i>Journal of Palliative Medicine</i> , 2009, 12, 1119-1124.	1.1	49
82	CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014064.	1.3	49
83	Epstein-Barr virus as a prognostic factor in nodal diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 66-72.	1.3	47
84	Extramedullary Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, 100-104.	4.1	47
85	The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2012, 36, 413-417.	0.8	45
86	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
87	Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e307-e310.	3.5	45
88	How we manage Bing-Neel syndrome. <i>British Journal of Haematology</i> , 2019, 187, 277-285.	2.5	45
89	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four <sc>CALGB</sc> (alliance) clinical trials. <i>American Journal of Hematology</i> , 2016, 91, 199-204.	4.1	44
90	Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 2689-2697.	4.1	43

#	ARTICLE	IF	CITATIONS
91	Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study. <i>American Journal of Hematology</i> , 2011, 86, 256-261.	4.1	42
92	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 181, 77-85.	2.5	41
93	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41
94	Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. <i>Leukemia and Lymphoma</i> , 2010, 51, 1822-1828.	1.3	38
95	Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: A meta-analysis of prospective cohort studies. <i>Leukemia Research</i> , 2014, 38, 1067-1071.	0.8	38
96	Obesity Is Associated With Increased Relative Risk of Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Observational Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 122-130.	0.4	36
97	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. <i>Oncologist</i> , 2016, 21, 1377-1386.	3.7	36
98	Human immunodeficiency virus-associated anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 430-438.	1.3	35
99	Plasma fatty acid profile in multiple myeloma patients. <i>Leukemia Research</i> , 2015, 39, 400-405.	0.8	35
100	Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus?. <i>Cardiovascular Pathology</i> , 2015, 24, 60-64.	1.6	35
101	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. <i>Blood Advances</i> , 2020, 4, 3952-3959.	5.2	35
102	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 435-445.	4.1	35
103	PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 355-361.	4.1	34
104	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	4.1	34
105	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenström macroglobulinemia. <i>Leukemia</i> , 2015, 29, 2338-2346.	7.2	34
106	Rituximab intolerance in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 174, 645-648.	2.5	34
107	The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. <i>Leukemia and Lymphoma</i> , 2016, 57, 58-62.	1.3	34
108	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. <i>Blood Cancer Journal</i> , 2020, 10, 12.	6.2	34

#	ARTICLE	IF	CITATIONS
109	Erythrocyte membrane fatty acids in multiple myeloma patients. <i>Leukemia Research</i> , 2014, 38, 1260-1265.	0.8	33
110	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>Cancer</i> , 2015, 121, 2230-2236.	4.1	33
111	<i>TP53</i> mutations are associated with mutated <i>MYD88</i> and <i>CXCR4</i> , and confer an adverse outcome in Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2019, 184, 242-245.	2.5	33
112	Multiple myeloma-induced hyperammonemic encephalopathy: An entity associated with high in-patient mortality. <i>Leukemia Research</i> , 2013, 37, 1229-1232.	0.8	32
113	Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. <i>Leukemia Research</i> , 2017, 62, 12-16.	0.8	32
114	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , 2021, 138, 1535-1539.	1.4	32
115	CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. <i>Expert Review of Hematology</i> , 2015, 8, 343-354.	2.2	31
116	Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. <i>Leukemia and Lymphoma</i> , 2017, 58, 1002-1004.	1.3	31
117	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	1.3	30
118	<i>MYD88</i> mutated and wild-type Waldenström Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i> . <i>Haematologica</i> , 2018, 103, e408-e411.	3.5	30
119	Meta-Analysis of the Association Between Cigarette Smoking and Incidence of Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3900-3906.	1.6	29
120	Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. <i>Annals of Oncology</i> , 2013, 24, 1352-1359.	1.2	29
121	Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. <i>Aids</i> , 2016, 30, 787-796.	2.2	29
122	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenström macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	1.4	29
123	CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. <i>Expert Review of Hematology</i> , 2019, 12, 873-881.	2.2	29
124	Cellular immunotherapy for refractory hematological malignancies. <i>Journal of Translational Medicine</i> , 2013, 11, 150.	4.4	28
125	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 179-186.	2.5	28
126	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	1.4	28

#	ARTICLE	IF	CITATIONS
127	Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies. <i>American Journal of Hematology</i> , 2012, 87, 330-333.	4.1	27
128	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2018, 59, 1375-1383.	1.3	27
129	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. <i>Blood Advances</i> , 2019, 3, 2800-2803.	5.2	27
130	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	1.4	27
131	Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. <i>Leukemia Research</i> , 2011, 35, 334-339.	0.8	26
132	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 951-965.	4.1	26
133	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 34-39.	2.0	25
134	Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 200-7.	2.8	25
135	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. <i>British Journal of Haematology</i> , 2014, 165, 300-315.	2.5	24
136	Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. <i>Leukemia and Lymphoma</i> , 2017, 58, 773-780.	1.3	24
137	Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	4.1	24
138	Management of Waldenström macroglobulinemia in 2020. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 372-379.	2.5	24
139	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenström Macroglobulinemia (WMCTG 09-214). <i>Clinical Cancer Research</i> , 2017, 23, 2400-2404.	7.0	23
140	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	1.3	23
141	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2020, 189, 1165-1170.	2.5	23
142	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenström's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1833-1833.	1.4	23
143	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016, 127, 2598-2606.	1.4	22
144	Plasma Cell Disorders. <i>Primary Care - Clinics in Office Practice</i> , 2016, 43, 677-691.	1.6	22

#	ARTICLE	IF	CITATIONS
145	CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. <i>Haematologica</i> , 2017, 102, e452-e455.	3.5	22
146	To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 176, 822-824.	2.5	22
147	Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 93-97.	1.7	22
148	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 2888-2888.	1.4	22
149	Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies. <i>Leukemia and Lymphoma</i> , 2012, 53, 1911-1919.	1.3	21
150	Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 945-970.	2.2	21
151	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	2.5	21
152	Risk factors associated with <i>Clostridium difficile</i> infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1617-1619.	1.3	20
153	Follicular lymphoma with leukemic phase at diagnosis: A series of seven cases and review of the literature. <i>Leukemia Research</i> , 2013, 37, 1116-1119.	0.8	20
154	Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: Report of four pediatric cases from Peru. <i>American Journal of Hematology</i> , 2014, 89, 1160-1161.	4.1	20
155	Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 866-873.	0.8	20
156	Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>American Journal of Hematology</i> , 2015, 90, 696-701.	4.1	20
157	MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 180, 578-581.	2.5	19
158	What is new in the treatment of Waldenström macroglobulinemia?. <i>Leukemia</i> , 2019, 33, 2555-2562.	7.2	19
159	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2019, 184, 1011-1014.	2.5	19
160	Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 354-361.	4.1	19
161	Plasmablastic lymphoma: Are more intensive regimens needed?. <i>Leukemia Research</i> , 2011, 35, 1547-1548.	0.8	18
162	Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. <i>Cancer Causes and Control</i> , 2015, 26, 1163-1172.	1.8	18

#	ARTICLE	IF	CITATIONS
163	Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1121-1129.	4.9	18
164	Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e466-e468.	3.5	18
165	Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia. <i>Cancer Treatment and Research</i> , 2015, 165, 177-195.	0.5	17
166	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018, 13, e0204589.	2.5	17
167	Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2093-2102.	1.3	17
168	Initial Evaluation of the Patient with Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 811-820.	2.2	16
169	Genomic Landscape of Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 745-752.	2.2	16
170	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. <i>American Journal of Hematology</i> , 2021, 96, 846-853.	4.1	16
171	Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 194, 730-733.	2.5	16
172	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. <i>Blood</i> , 2021, 138, 1966-1979.	1.4	16
173	Hematopoietic SCT for adult T-cell leukemia/lymphoma: a review. <i>Bone Marrow Transplantation</i> , 2011, 46, 1039-1044.	2.4	15
174	Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. <i>American Journal of Hematology</i> , 2018, 93, E1-E3.	4.1	15
175	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. <i>JCO Global Oncology</i> , 2021, 7, 1151-1166.	1.8	15
176	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e624.	2.7	15
177	Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 151-160.	2.4	14
178	Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 106-115.	2.5	14
179	The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 650-653.	2.5	14
180	ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7521-7521.	1.6	14

#	ARTICLE	IF	CITATIONS
181	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. American Journal of Hematology, 2015, 90, E122-3.	4.1	13
182	Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. British Journal of Haematology, 2017, 177, 808-813.	2.5	13
183	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	1.3	13
184	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Advances, 2020, 4, 141-153.	5.2	13
185	EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier. Infectious Agents and Cancer, 2009, 4, 10.	2.6	12
186	Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. Leukemia and Lymphoma, 2013, 54, 1647-1651.	1.3	12
187	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 639-656.	2.2	12
188	Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. British Journal of Haematology, 2019, 185, 788-790.	2.5	12
189	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363.	2.7	12
190	CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98.	4.1	12
191	Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM). Blood, 2015, 126, 2745-2745.	1.4	12
192	Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	5.2	12
193	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances, 2022, 6, 2035-2044.	5.2	12
194	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. HemaSphere, 2020, 4, e433.	2.7	11
195	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	4.1	11
196	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	3.5	11
197	Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 4004-4004.	1.4	11
198	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	3.5	11

#	ARTICLE	IF	CITATIONS
199	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.4	11
200	<scp>CD</scp>20â€negative diffuse large <scp>B</scp>â€cell lymphoma presenting with lactic acidosis. <i>American Journal of Hematology</i> , 2015, 90, E49-50.	4.1	10
201	Prognostic Factors for Survival in 60 Patients with Classical Hodgkin Lymphoma From Peru. <i>Blood</i> , 2011, 118, 4863-4863.	1.4	10
202	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic WaldenstrÃ¶m macroglobulinemia. <i>Blood Advances</i> , 2022, 6, 2230-2235.	5.2	10
203	Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review. <i>Journal of HIV Therapy</i> , 2009, 14, 34-40.	0.6	10
204	Diffuse Large B-Cell Lymphoma in Human T-Lymphotropic Virus Type 1 Carriers. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-4.	2.0	9
205	Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies. <i>OncoTargets and Therapy</i> , 2014, 7, 333.	2.0	9
206	Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. <i>Future Oncology</i> , 2014, 10, 1147-1155.	2.4	9
207	The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2018, 67, 82-85.	0.8	9
208	High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e551-e557.	0.4	9
209	Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e39-e40.	0.4	9
210	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1388-1394.	1.3	9
211	Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2886-2886.	1.4	9
212	A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. <i>Blood</i> , 2018, 132, 40-40.	1.4	9
213	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7566-7566.	1.6	9
214	No association between cigarette smoking and incidence of plasma cell myeloma: A meta-analysis of 17 observational studies. <i>American Journal of Hematology</i> , 2012, 87, 729-731.	4.1	8
215	Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literature. <i>Leukemia and Lymphoma</i> , 2013, 54, 2306-2309.	1.3	8
216	Partial response or better at six months is prognostic of superior progression-free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	2.5	8

#	ARTICLE	IF	CITATIONS
217	Cell-free DNA analysis for detection of MYD88 ^{L265P} and CXCR4 ^{S338X} mutations in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, E250-E253.	4.1	8
218	Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+LBCL): a systematic review of clinicopathological features and management. <i>Leukemia and Lymphoma</i> , 2021, 62, 2845-2853.	1.3	8
219	Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. <i>Blood</i> , 2012, 120, 5002-5002.	1.4	8
220	Peripheral T-cell Lymphoma With a Regulatory T-cell Phenotype. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 196-200.	1.2	7
221	Similar survival outcomes in patients with biconal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	1.8	7
222	Toward personalized treatment in Waldenström macroglobulinemia. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 365-370.	2.5	7
223	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 640-640.	1.4	7
224	Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2022, 198, .	2.5	7
225	Complete Remission in Two Cases of Adult T-Cell Leukemia/Lymphoma Treated With Hyper-CVAD: A Case Report and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 480-483.	0.4	6
226	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. <i>Leukemia and Lymphoma</i> , 2011, 52, 153-156.	1.3	6
227	Why is My Patient Neutropenic?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 253-266.	2.2	6
228	Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2013, 37, 386-391.	0.8	6
229	Improving the accuracy in prognosis for Burkitt lymphoma patients. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 125-127.	2.4	6
230	Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. <i>Expert Review of Hematology</i> , 2017, 10, 739-744.	2.2	6
231	True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. <i>Haematologica</i> , 2018, 103, e374-e376.	3.5	6
232	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241.	4.1	6
233	Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. <i>Cancer</i> , 2019, 125, 550-558.	4.1	6
234	Deepening of response after completing rituximab-containing therapy in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 372-378.	4.1	6

#	ARTICLE	IF	CITATIONS
235	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	1.3	6
236	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 547-556.	0.4	6
237	The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. <i>Journal of Blood Medicine</i> , 2010, 1, 1.	1.7	5
238	The girl with the iron tattoo. <i>Virulence</i> , 2012, 3, 599-600.	4.4	5
239	Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. <i>American Journal of Hematology</i> , 2016, 91, E324.	4.1	5
240	Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1753-1755.	1.3	5
241	How to Sequence Therapies in Waldenström Macroglobulinemia. <i>Current Treatment Options in Oncology</i> , 2021, 22, 92.	3.0	5
242	Complete response to pembrolizumab and radiation in a patient with <sc>HIV</sc>-negative, <sc>EBV</sc>-positive plasmablastic lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E390-E392.	4.1	5
243	What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. <i>Blood Advances</i> , 2017, 1, 2486-2490.	5.2	5
244	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	1.7	5
245	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 5089-5092.	5.2	5
246	Future therapeutic options for patients with Waldenström macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 206-215.	1.7	4
247	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. <i>Leukemia and Lymphoma</i> , 2016, 57, 2699-2701.	1.3	4
248	Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. <i>British Journal of Haematology</i> , 2019, 185, 799-802.	2.5	4
249	An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 315-325.	1.3	4
250	Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2018, 132, 1566-1566.	1.4	4
251	Association Between Obesity/Overweight and Leukemia: A Meta-Analysis of Prospective Cohort Studies. <i>Blood</i> , 2011, 118, 3588-3588.	1.4	4
252	Adult T-Cell Leukemia/Lymphoma in Peru: A Report of 120 Cases. <i>Blood</i> , 2012, 120, 5110-5110.	1.4	4

#	ARTICLE	IF	CITATIONS
253	Updated results of the ASPEN trial from a cohort of patients with <i>MYD88</i> wild-type (<i>MYD88</i>^{WT}) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, e20056-e20056.	1.6	4
254	The Risk of Lymphoproliferative Disorders In Patients with Diabetes Mellitus: A Meta-Analysis. Blood, 2010, 116, 3108-3108.	1.4	4
255	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	5.2	4
256	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338.	5.2	4
257	Extranodal Marginal Zone Lymphoma From Ocular Adnexae With Subcutaneous Involvement. American Journal of Dermatopathology, 2014, 36, e189-e193.	0.6	3
258	Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. Leukemia Research, 2015, 39, 812-817.	0.8	3
259	Survival Claims From Observational Data on Cancer Therapy. Journal of Clinical Oncology, 2016, 34, 1425-1427.	1.6	3
260	Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. Blood Advances, 2020, 4, 4550-4553.	5.2	3
261	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 637-646.	0.4	3
262	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3
263	Clinical application of genomics in Waldenström macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	1.3	3
264	The Relationship Between Obesity and Lymphoma: A Meta-Analysis of Prospective Cohort Studies. Blood, 2011, 118, 5198-5198.	1.4	3
265	Grey Zone Lymphoma, Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: Better Results With CHOP-Like Regimens. Blood, 2013, 122, 5105-5105.	1.4	3
266	The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival. Blood, 2015, 126, 4974-4974.	1.4	3
267	HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 705-705.	1.4	3
268	Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88. Blood, 2015, 126, 2665-2665.	1.4	3
269	Images in HIV/AIDS. Fatal HIV-associated anaplastic large-cell lymphoma. Aids Reader, 2009, 19, 19-21.	0.3	3
270	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy, 2022, , .	2.4	3

#	ARTICLE	IF	CITATIONS
271	Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: A unifying diagnosis. <i>American Journal of Hematology</i> , 2011, 86, 690-693.	4.1	2
272	Not All Aggressive Adult T-Cell Leukemia/Lymphoma Subtypes Are Created Equal. <i>Journal of Clinical Oncology</i> , 2012, 30, 3560-3560.	1.6	2
273	Bing-Neel syndrome: a rare complication of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 126, 1390-1390.	1.4	2
274	The real world of Waldenström's macroglobulinaemia. <i>Lancet Haematology</i> , 2018, 5, e275-e276.	4.6	2
275	Reducing treatment toxicity in Waldenström macroglobulinemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	2
276	Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 195, 466-468.	2.5	2
277	Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL). <i>Blood</i> , 2019, 134, 4045-4045.	1.4	2
278	Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL). <i>Blood</i> , 2020, 136, 18-21.	1.4	2
279	Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenström's Macroglobulinemia and IgM MGUS. <i>Blood</i> , 2015, 126, 3926-3926.	1.4	2
280	HIV-Associated NK/T-Cell Lymphomas: A Review of 93 Cases.. <i>Blood</i> , 2007, 110, 3457-3457.	1.4	2
281	The Immunohistochemical Profile and Other Prognostic Factors In Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2010, 116, 4126-4126.	1.4	2
282	Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma. <i>Pathology Research International</i> , 2011, 2011, 1-5.	1.4	2
283	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , 2012, 120, 2728-2728.	1.4	2
284	Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19. <i>Revista Colombiana De Cancerología</i> , 2022, 24, .	0.2	2
285	When a Monoclonal Gammopathy Is Not Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 655-664.	3.8	2
286	Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. <i>Leukemia and Lymphoma</i> , 2022, 63, 1137-1143.	1.3	2
287	Primary refractory Hodgkin lymphoma: Limited options and poor survival—but not always. <i>American Journal of Hematology</i> , 2014, 89, 853-857.	4.1	1
288	Cancer-Related Hyponatremia: Enhancing Recognition and Improving Management. <i>Clinical Lung Cancer</i> , 2016, 17, e29.	2.6	1

#	ARTICLE	IF	CITATIONS
289	Genetic and Signaling Abnormalities in Waldenstrom's Macroglobulinemia. , 2017, , 53-65.		1
290	Comparing apples to oranges: A commentary on the <sc>M</sc>ayo study of <sc>MYD</sc>88 significance in <sc>W</sc>aldenstrom's macroglobulinemia.. American Journal of Hematology, 2018, 93, E69-E71.	4.1	1
291	Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, E201.	4.1	1
292	Genomic landscape of Waldenström's macroglobulinemia. HemaSphere, 2019, 3, 58-61.	2.7	1
293	HOLA! from Latin America to the myeloma world. British Journal of Haematology, 2020, 188, 349-350.	2.5	1
294	Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leukemia Research, 2021, 102, 106513.	0.8	1
295	EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly. , 2012, , 83-98.		1
296	Non-Hodgkin Lymphoma and Smoking: A Meta-Analysis of Case-Control Studies. Blood, 2008, 112, 5292-5292.	1.4	1
297	Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies. Blood, 2013, 122, 832-832.	1.4	1
298	Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia. Blood, 2015, 126, 128-128.	1.4	1
299	Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2015, 126, 3914-3914.	1.4	1
300	Low-Dose Bexarotene and Phototherapy or Interferon Alfa-2a in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma. Blood, 2008, 112, 5010-5010.	1.4	1
301	HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study. Blood, 2011, 118, 1589-1589.	1.4	1
302	Follicular Lymphoma in Latin America: Real-World Experience from 763 Patients. Blood, 2020, 136, 12-13.	1.4	1
303	Bone marrow aspiration in a patient with systemic microsporidium. Clinical Case Reports (discontinued), 2022, 10, .	0.5	1
304	A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM).. Journal of Clinical Oncology, 2022, 40, e19522-e19522.	1.6	1
305	A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. EJHaem, 2022, 3, 927-929.	1.0	1
306	Noteworthy Features of HIV-associated T-cell Non-Hodgkin lymphoma. HIV and AIDS Review, 2007, 6, 26-30.	0.2	0

#	ARTICLE	IF	CITATIONS
307	Extramedullary relapse of acute myeloid leukemia in a surgical wound. <i>Leukemia and Lymphoma</i> , 2011, 52, 541-543.	1.3	0
308	Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2012, 2012, 1-6.	0.4	0
309	R-CHOP versus CHOP in HIV-associated lymphoma: a meta-analysis of prospective studies. <i>Infectious Agents and Cancer</i> , 2012, 7, .	2.6	0
310	Reply to A. Messori et al.. <i>American Journal of Hematology</i> , 2013, 88, 435-436.	4.1	0
311	12. Waldenström's macroglobulinemia. , 2016, , 229-244.		0
312	Risk factors for progression from smoldering into active myeloma: additional insights from a population-based study. <i>European Journal of Haematology</i> , 2016, 97, 217-218.	2.2	0
313	“All the soarings of my mind begin in my blood:” central nervous system complication of Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1057-1060.	4.1	0
314	Signal Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 327-334.		0
315	Immunomodulatory Agents and Proteasome Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 335-343.		0
316	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2018, 4, 744.	7.1	0
317	1130. Low Risk of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Waldenström's Macroglobulinemia on Ibrutinib. <i>Open Forum Infectious Diseases</i> , 2018, 5, S338-S339.	0.9	0
318	Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, xiii-xiv.	2.2	0
319	Viral lymphomagenesis: beyond the usual suspects. <i>British Journal of Haematology</i> , 2018, 182, 617-618.	2.5	0
320	Monoclonal Antibodies for Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 841-852.	2.2	0
321	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
322	Reply to F.D. Leonard. <i>Journal of Clinical Oncology</i> , 2019, 37, 2701-2702.	1.6	0
323	Special Issues in Pregnancy. , 2020, , 882-893.e3.		0
324	Prognostic value of disease risk score versus gait speed in older adults with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	0

#	ARTICLE	IF	CITATIONS
325	Novel Agents for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S34-S35.	0.4	0
326	Tailoring Therapy in Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S59-S60.	0.4	0
327	Epstein-Barr Virus Status as Prognostic Factor in Nodal Diffuse Large B-Cell Lymphoma in Elderly Patients. <i>Blood</i> , 2008, 112, 5301-5301.	1.4	0
328	Immunohistochemical Expression of Germinal Center and Non-Germinal Center Markers in Primary Gastric Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 5276-5276.	1.4	0
329	ALK-Positive Diffuse Large B-Cell Lymphoma: Report of Four Cases from Peru. <i>Blood</i> , 2008, 112, 4967-4967.	1.4	0
330	Immunohistochemical Expression Pattern of Germinal Center and Non-Germinal Center Markers in Age-Related Epstein Barr Virus-Associated B-Cell Lymphoproliferative Disorder. <i>Blood</i> , 2008, 112, 5289-5289.	1.4	0
331	Smoking and Hodgkin Lymphoma: A Meta-Analysis. <i>Blood</i> , 2008, 112, 4829-4829.	1.4	0
332	Clinical Characteristics and Outcomes of 102 Patients with Adult T-Cell Leukemia/Lymphoma in Peru.. <i>Blood</i> , 2009, 114, 5001-5001.	1.4	0
333	Clinicopathologic Characteristics of HIV-Associated Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3924-3924.	1.4	0
334	Clinical Outcome and Survival of EBV-Positive Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 5005-5005.	1.4	0
335	The Association Between Red Blood Cell Transfusions and Development of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 1376-1376.	1.4	0
336	Prognostic Factors in Aggressive, Non-Primary Cutaneous Peripheral T-Cell Lymphoma in Peru: A Study of 227 Cases.. <i>Blood</i> , 2009, 114, 5021-5021.	1.4	0
337	Lymphopenia Predicts Survival in Peripheral T-Cell Lymphoma, Unspecified.. <i>Blood</i> , 2009, 114, 1930-1930.	1.4	0
338	Low-Dose Bexarotene Alone or in Combination for the Treatment of Relapsed or Refractory Cutaneous T-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 4790-4790.	1.4	0
339	The Association Between Smoking and Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 2560-2560.	1.4	0
340	Prevalence and Prognostic Factors of EBV-Positive DLBCL of the Elderly In Peru. <i>Blood</i> , 2010, 116, 4166-4166.	1.4	0
341	Quantification of EBV DNA In Whole Blood In Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 3102-3102.	1.4	0
342	Clinicopathological Differences Between Asian and Western Patients with De Novo Diffuse Large B Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2011, 118, 2665-2665.	1.4	0

#	ARTICLE	IF	CITATIONS
343	R-CHOP in the Treatment of EBV-Diffuse Large B-Cell Lymphoma of the Elderly. <i>Blood</i> , 2011, 118, 4988-4988.	1.4	0
344	HIV Infection and Cancer: Multi-Institutional Collaboration is the Answer. <i>Journal of AIDS & Clinical Research</i> , 2012, 03, .	0.5	0
345	Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8045-8045.	1.6	0
346	Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis.. <i>Blood</i> , 2012, 120, 2658-2658.	1.4	0
347	Higher Body Mass Index Is Associated with an Increased Risk of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1605-1605.	1.4	0
348	Survival and Clinicopathological Characteristics of EBV-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1588-1588.	1.4	0
349	Spontaneous Remission of Chronic Lymphocytic Leukemia, Possibly More Rare Than Previously Reported?. <i>Blood</i> , 2012, 120, 4589-4589.	1.4	0
350	Monocytosis As Prognostic Factor in Aggressive, Non-Primary Cutaneous Peripheral T-Cell Lymphoma: A Study of 251 Cases. <i>Blood</i> , 2012, 120, 1608-1608.	1.4	0
351	Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases. <i>Blood</i> , 2012, 120, 1528-1528.	1.4	0
352	Vertebral Compression Fractures in Patients with Chronic Lymphocytic Leukemia: Incidence and Risk Factors. <i>Blood</i> , 2012, 120, 4586-4586.	1.4	0
353	Prognostic Factors in Peripheral T-Cell Lymphomas. , 2013, , 141-152.		0
354	Prognostic Factors in HIV-Associated Lymphoma. , 2013, , 153-169.		0
355	Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab-Containing Regimen: A Brown University Oncology Research Group Phase II Study. <i>Blood</i> , 2013, 122, 5121-5121.	1.4	0
356	Special Issues in Pregnancy. , 2014, , 914-925.e3.		0
357	Survival in patients with metastatic prostate cancer in Peru.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16110-e16110.	1.6	0
358	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19561-e19561.	1.6	0
359	Prognosis of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). <i>Blood</i> , 2015, 126, 3861-3861.	1.4	0
360	High Rates of HTLV-1 Seropositivity in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5049-5049.	1.4	0

#	ARTICLE	IF	CITATIONS
361	The Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5047-5047.	1.4	0
362	CD20-Negative Aggressive Lymphomas. <i>Mechanical Engineering Series</i> , 2019, , 213-226.	0.2	0
363	Plasmablastic Lymphoma and Primary Effusion Lymphoma. , 2020, , 101-118.		0
364	Novel Therapeutics in the Management of Waldenström Macroglobulinemia. , 2020, , 15-26.		0
365	Linfoma/Leucemia T del adulto: Entidad prevalente en Sudamérica. <i>Revista De La Facultad De Medicina Humana</i> , 2020, 20, 12-13.	0.2	0
366	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
367	Primary cutaneous Epstein-Barr virus-positive B-cell lymphoid proliferation with features of diffuse large B-cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. <i>International Journal of Dermatology</i> , 2022, , .	1.0	0
368	A British view on the management of Waldenström macroglobulinemia – Response to Pratt et al .. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
369	AIDS-related lymphomas: the Rhode Island experience. <i>Medicine and Health, Rhode Island</i> , 2008, 91, 332-4.	0.1	0